What the company does
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 …
What the weekly tape is saying
ORY closed the latest completed week at 3.14 EUR. The 4-week return is 11.7% and the 12-week return is 15.1%. Trend Signal is inactive, Market Dynamics is 0.92. Setup signature: Deep recovery attempt with a 57/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 3.01 EUR
- Vs Trend Line
- 4.3%
- Fair Value
- 2.34 EUR
- Vs Fair Value
- 34.1%
- 52W High
- 4.02 EUR
- 52W Low
- 2.56 EUR
- Drawdown
- -21.8%
- Range Position
- 40.1%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 32
- 52W Active Breadth
- 61.5%
- Sector Scope
- ES Healthcare
- Sector Rank
- 1 of 14
- Sector Percentile
- 100.0%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
ES Healthcare
- Tracked Peers
- 14
- 4W Rank
- 1 of 14
- Avg 1W
- -3.1%
- Avg 4W
- -0.9%
- Trend Breadth
- 42.9%
- Positive MD
- 57.1%
ES Biotechnology
- Tracked Peers
- 5
- 4W Rank
- 1 of 5
- Avg 1W
- -7.5%
- Avg 4W
- -4.0%
- Trend Breadth
- 60.0%
- Positive RS
- 20.0%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- 0.92
- 4W MD Change
- 174.2%
- Relative Strength
- -8.13
- 4W RS Change
- 39.3%
- Expectation
- Negative
- Probability
- 38.27%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 3.0M
- 13W Average
- 1.7M
- 52W Average
- 3.0M
- Vs 13W
- 1.7x
- Vs 52W
- 1.0x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 3.6%
- 52W Volatility
- 5.7%
- Upside Weeks
- 23
- Downside Weeks
- 27
- Downside Breadth
- 51.9%
- Avg Gain / Loss
- 5.0% / -3.6%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- MCE
- Country
- ES
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- EUR
- Market Cap
- 241.6M
Opportunity signals
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Market Dynamics is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
- Latest weekly return ranks in the strongest part of its sector group.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 3.14 EUR | 4.9% | 3.01 EUR | 2.34 EUR | 0.92 | -8.13 | 3.0M | Off |
| 5 Jun 2026 | 2.99 EUR | -4.8% | 3.01 EUR | 2.34 EUR | 0.41 | -10.76 | 2.2M | Off |
| 29 May 2026 | 3.14 EUR | 3.8% | 3.02 EUR | 2.33 EUR | -0.11 | -6.74 | 3.0M | Off |
| 22 May 2026 | 3.03 EUR | 7.6% | 3.03 EUR | 2.33 EUR | -0.73 | -8.48 | 3.1M | Off |
| 15 May 2026 | 2.81 EUR | 3.2% | 3.04 EUR | 2.32 EUR | -1.23 | -13.39 | 1.1M | Off |
| 8 May 2026 | 2.73 EUR | -2.1% | 3.06 EUR | 2.31 EUR | -1.29 | -17.60 | 1.2M | Off |
| 1 May 2026 | 2.78 EUR | -0.2% | 3.09 EUR | 2.31 EUR | -1.27 | -15.77 | 984.3K | Off |
| 24 Apr 2026 | 2.79 EUR | -3.1% | 3.11 EUR | 2.31 EUR | -1.29 | -15.52 | 1.0M | Off |
| 17 Apr 2026 | 2.88 EUR | 1.4% | 3.12 EUR | 2.30 EUR | -1.32 | -16.93 | 1.5M | Off |
| 10 Apr 2026 | 2.84 EUR | 1.8% | 3.13 EUR | 2.30 EUR | -1.45 | -17.29 | 1.3M | Off |
| 3 Apr 2026 | 2.79 EUR | 4.1% | 3.12 EUR | 2.29 EUR | -1.50 | -16.31 | 1.1M | Off |
| 27 Mar 2026 | 2.68 EUR | -1.8% | 3.12 EUR | 2.29 EUR | -1.51 | -16.50 | 2.0M | Off |
| 20 Mar 2026 | 2.73 EUR | -3.2% | 3.12 EUR | 2.29 EUR | -1.24 | -15.21 | 1.0M | Off |
| 13 Mar 2026 | 2.82 EUR | 1.8% | 3.12 EUR | 2.28 EUR | -0.99 | -14.87 | 1.8M | Off |